- Home
- FLS vs LEGN Comparison
FLS vs LEGN Comparison
Compare FLS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLS
- LEGN
- Stock Information
- Founded
- FLS 1790
- LEGN 2014
- Country
- FLS United States
- LEGN United States
- Employees
- FLS N/A
- LEGN N/A
- Industry
- FLS Fluid Controls
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- FLS Industrials
- LEGN Health Care
- Exchange
- FLS Nasdaq
- LEGN Nasdaq
- Market Cap
- FLS 8.3B
- LEGN 7.0B
- IPO Year
- FLS N/A
- LEGN 2020
- Fundamental
- Price
- FLS $52.11
- LEGN $31.08
- Analyst Decision
- FLS Strong Buy
- LEGN Strong Buy
- Analyst Count
- FLS 9
- LEGN 13
- Target Price
- FLS $64.11
- LEGN $79.42
- AVG Volume (30 Days)
- FLS 1.8M
- LEGN 1.6M
- Earning Date
- FLS 04-29-2025
- LEGN 05-13-2025
- Dividend Yield
- FLS 1.60%
- LEGN N/A
- EPS Growth
- FLS 20.22
- LEGN N/A
- EPS
- FLS 2.14
- LEGN N/A
- Revenue
- FLS $4,614,870,000.00
- LEGN $728,303,000.00
- Revenue This Year
- FLS $6.43
- LEGN $65.96
- Revenue Next Year
- FLS $3.77
- LEGN $52.55
- P/E Ratio
- FLS $24.46
- LEGN N/A
- Revenue Growth
- FLS 4.23
- LEGN 112.46
- 52 Week Low
- FLS $37.34
- LEGN $29.27
- 52 Week High
- FLS $65.08
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- FLS 69.85
- LEGN 39.41
- Support Level
- FLS $46.34
- LEGN $30.25
- Resistance Level
- FLS $47.89
- LEGN $33.30
- Average True Range (ATR)
- FLS 1.37
- LEGN 1.53
- MACD
- FLS 0.98
- LEGN -0.18
- Stochastic Oscillator
- FLS 96.73
- LEGN 26.21
About FLS Flowserve Corporation
Flowserve Corp is a manufacturer and aftermarket service provider of comprehensive flow control systems. It develops precision-engineered flow control equipment to monitor movement and protect customers' materials and processes. It offers an extensive range of pumps, valves, seals, and services for several industries, including oil and gas, chemical, power generation, and water management. In addition, Flowserve has a network of Quick Response Centers to provide aftermarket equipment services. The aftermarket services help customers with installation, diagnostics, repair, and retrofitting. Sales are roughly split across many regions, with North America and Europe contributing the majority of total revenue.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.